ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -20 مورد

Anifrolumab: Drug information

Anifrolumab: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Anifrolumab: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Saphnelo
Brand Names: Canada
  • Saphnelo
Pharmacologic Category
  • Immune Globulin;
  • Interferon Receptor Antagonist, Type I;
  • Monoclonal Antibody
Dosing: Adult

Note: Consider premedication in patients with a history of hypersensitivity or infusion reactions.

Systemic lupus erythematosus, moderate to severe

Systemic lupus erythematosus, moderate to severe: IV: 300 mg every 4 weeks.

Missed doses : Administer a missed dose as soon as possible but maintain at least 14 days between infusions.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Adverse Reactions (Significant): Considerations
Hypersensitivity reactions

Hypersensitivity reactions, including severe hypersensitivity reactions (ie, anaphylaxis and angioedema), have been reported. Most cases were considered mild or moderate intensity.

Onset: Varied; most reactions occurred during the first 12 weeks of treatment (ie, with the first 3 to 4 infusions) (Ref).

Infections

Infections occurred in clinical trials during anifrolumab treatment; severe infection occurred at a much lower rate of incidence, although fatal infections were reported. The most frequently reported types of infections across all clinical trials were respiratory tract infection (ie, nasopharyngitis, pharyngitis, pneumonia, upper respiratory tract infection) and herpes zoster infection, including cases of cutaneous (Ref) and disseminated herpes zoster.

Mechanism: Dose-dependent; anifrolumab binds to type I interferon receptors (IFNAR) and blocks the activity of type I interferons, thereby reducing production of proinflammatory and immunomodulatory proteins involved immune response (ie, B-cell, T-cell, and other immune cell migrations (Ref); cytokines (TNF-α, IL-6); CD80 and CD83 expression of dendritic cells (Ref)

Malignancy

Immunosuppressant therapy may increase the risk of malignancy. Impact on the development and course of malignancies is not fully defined; however, malignancies were observed in clinical trials. Malignant neoplasm (including malignant neoplasm of breast, squamous cell carcinoma) were rarely reported.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%:

Infection: Infection (70%, including influenza, tuberculosis [Tanaka 2021], urinary tract infection; severe infection: 5%) (table 1)

Anifrolumab: Adverse Reaction: Infection

Drug (Anifrolumab)

Placebo

Number of Patients (Anifrolumab)

Number of Patients (Placebo)

Comments

70%

55%

459

466

N/A

5%

6%

459

466

Severe infection

Respiratory: Bronchitis (11%), upper respiratory tract infection (34%; including nasopharyngitis, pharyngitis, sinusitis [Tanaka 2021]) (table 2)

Anifrolumab: Adverse Reaction: Upper Respiratory Tract Infection

Drug (Anifrolumab)

Placebo

Number of Patients (Anifrolumab)

Number of Patients (Placebo)

34%

23%

459

466

1% to 10%:

Hematologic & oncologic: Malignant neoplasm (1%; including malignant neoplasm of breast, squamous cell carcinoma) (table 3)

Anifrolumab: Adverse Reaction: Malignant Neoplasm

Drug (Anifrolumab)

Placebo

Number of Patients (Anifrolumab)

Number of Patients (Placebo)

1%

0.6%

459

466

Hypersensitivity: Hypersensitivity reaction (3%; including anaphylaxis [<1%], angioedema [<1%], severe hypersensitivity reaction [<1%]) (table 4), infusion-related reaction (9%)

Anifrolumab: Adverse Reaction: Hypersensitivity Reaction

Drug (Anifrolumab)

Placebo

Number of Patients (Anifrolumab)

Number of Patients (Placebo)

3%

0.6%

459

466

Immunologic: Antibody development (2%)

Infection: Herpes zoster infection (6%) (table 5)

Anifrolumab: Adverse Reaction: Herpes Zoster Infection

Drug (Anifrolumab)

Placebo

Number of Patients (Anifrolumab)

Number of Patients (Placebo)

6%

1%

459

466

Respiratory: Cough (5%), respiratory tract infection (3%) (table 6)

Anifrolumab: Adverse Reaction: Respiratory Tract Infection

Drug (Anifrolumab)

Placebo

Number of Patients (Anifrolumab)

Number of Patients (Placebo)

3%

2%

459

466

Frequency not defined: Respiratory: Pneumonia

Postmarketing: Neuromuscular & skeletal: Arthralgia

Contraindications

Severe hypersensitivity (eg, anaphylaxis) to anifrolumab or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Infusion reactions: Infusion reactions have been reported. Discontinue treatment and initiate supportive treatment in patients who develop infusion-related reactions.

Other warnings/precautions:

• Appropriate use: Concurrent use with other biologic therapies, including B-cell–targeted therapies, is not recommended; has not been studied.

• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live or live attenuated vaccines should not be given concurrently.

• Infections: Carefully consider risk versus benefit in patients with chronic or recurrent infections or known risk factors for infection. Avoid initiating treatment in patients with a significant active infection until the infection resolves or is adequately treated.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Saphnelo: Anifrolumab-fnia 300 mg/2 mL (2 mL) [contains polysorbate 80]

Generic Equivalent Available: US

No

Pricing: US

Solution (Saphnelo Intravenous)

300 mg/2 mL (per mL): $3,200.38

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Saphnelo: Anifrolumab-fnia 300 mg/2 mL (2 mL) [contains polysorbate 80]

Administration: Adult

IV: Allow refrigerated solution to reach room temperature prior to administration. Administer by IV infusion using a low-protein binding 0.2 to 15 micron in-line or add-on filter over 30 minutes. Flush infusion set with 25 mL of NS upon completion. Do not administer other medication through same line.

Use: Labeled Indications

Systemic lupus erythematosus, moderate to severe: Treatment of moderate to severe systemic lupus erythematosus in adults who are receiving standard therapy.

Limitations of use: Efficacy has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Abrocitinib: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor

Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Baricitinib. Risk X: Avoid

BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of BCG Products. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Belimumab: Anifrolumab may increase immunosuppressive effects of Belimumab. Risk X: Avoid

Biologic Anti-Psoriasis Agents: May increase immunosuppressive effects of Anifrolumab. Risk X: Avoid

Biologic Disease-Modifying Antirheumatic Drugs: May increase immunosuppressive effects of Anifrolumab. Risk X: Avoid

Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Brincidofovir. Risk C: Monitor

Brivudine: May increase adverse/toxic effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Chikungunya Vaccine (Live). Risk X: Avoid

Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Cladribine. Risk X: Avoid

Coccidioides immitis Skin Test: Coadministration of Immunosuppressants (Therapeutic Immunosuppressant Agents) and Coccidioides immitis Skin Test may alter diagnostic results. Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor

COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of COVID-19 Vaccine (Subunit). Risk C: Monitor

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Dengue Tetravalent Vaccine (Live). Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections. Risk D: Consider Therapy Modification

Deucravacitinib: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Efgartigimod Alfa: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Etrasimod: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Filgotinib: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Inebilizumab. Risk C: Monitor

Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored. Risk D: Consider Therapy Modification

Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider Therapy Modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid

Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Natalizumab. Risk X: Avoid

Nipocalimab: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ocrelizumab. Risk C: Monitor

Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ofatumumab. Risk C: Monitor

Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Pidotimod. Risk C: Monitor

Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Pimecrolimus. Risk X: Avoid

Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Pneumococcal Vaccines. Risk C: Monitor

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase hypersensitivity effects of Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider Therapy Modification

Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider Therapy Modification

Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ritlecitinib. Risk X: Avoid

Rozanolixizumab: May decrease therapeutic effects of Fc Receptor-Binding Agents. Risk C: Monitor

Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ruxolitinib (Topical). Risk X: Avoid

Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider Therapy Modification

Sphingosine 1-Phosphate (S1P) Receptor Modulators: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk C: Monitor

Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Tacrolimus (Topical). Risk X: Avoid

Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid

Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Tertomotide. Risk X: Avoid

Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials. Risk X: Avoid

Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Typhoid Vaccine. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ublituximab. Risk C: Monitor

Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Upadacitinib. Risk X: Avoid

Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Vaccines (Live). Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to starting immunosuppressants when possible. Patients vaccinated less than 14 days before or during therapy should be revaccinated at least 2 to 3 months after therapy is complete. Risk D: Consider Therapy Modification

Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Yellow Fever Vaccine. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Zoster Vaccine (Live/Attenuated): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Zoster Vaccine (Live/Attenuated). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Zoster Vaccine (Live/Attenuated). Risk X: Avoid

Pregnancy Considerations

Anifrolumab is a humanized monoclonal antibody (IgG1). Human IgG is known to cross the placenta; exposure is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).

Data collection to monitor pregnancy and infant outcomes following exposure to anifrolumab is ongoing. Health care providers are encouraged to enroll patients exposed to anifrolumab during pregnancy in the Pregnancy Registry (1-877-693-9268).

Breastfeeding Considerations

It is not known if anifrolumab is present in breast milk; however, anifrolumab is a humanized monoclonal antibody (IgG1). Human IgG is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Monitoring Parameters

Signs and symptoms of hypersensitivity and infection.

Mechanism of Action

Anifrolumab is an IgG1-kappa monoclonal antibody that blocks the biologic activity of type 1 interferon receptors (IFNAR); elevated IFNAR plays a role in the pathogenesis of systemic lupus erythematosus. This reduces inflammatory and immunological processes.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vdss: 6.23 L.

Excretion: Clearance: 0.193 L/day.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (QA) Qatar: Saphnelo
  1. Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-1543. doi:10.2147/DDDT.S170969 [PubMed 31190735]
  2. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi:10.1155/2012/985646 [PubMed 22235228]
  3. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344. doi:10.1002/bdrb.20201 [PubMed 19626656]
  4. Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi:10.1136/lupus-2018-000261 [PubMed 29644082]
  5. Saphnelo (anifrolumab) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2024.
  6. Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol. 2021;31(1):1-12. doi:10.1080/14397595.2020.1812201 [PubMed 32814461]
  7. Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. doi:10.1136/lupus-2020-000464 [PubMed 33597205]
Topic 132266 Version 81.0